Northwest Bio gains key regulatory approval in Germany

|About: Northwest Biotherapeut... (NWBO)|By:, SA News Editor

Northwest Biotherapeutics (NWBO) gets a "Hospital Exemption" early access program for DCVax-L from German regulators. This means that the company may provide the product to patients for the treatment of Glioblastoma multforme and lower grades of gliomas outside of its clinical trial and charge full price.

The approval term is five years.

The German reimbursement authority approves DCVax-L eligibility for reimbursement from the Sickness Funds (health insurers). The specific level of payment will be negotiated by the company, hospitals and insurers.